Showing results (91-100 of 170) with videos related to
Sort By:
Pageof 17
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2021
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseAnastasia Gangaev, Elisa A Rozeman, Maartje W Rohaan, et al.Investigative Ophthalmology & Visual Science|July 13, 2017
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaSimone L Scholz, Inga Möller, Henning Reis, et al.Cancer Immunology, Immunotherapy : CII|June 14, 2016
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisMarkus V Heppt, Thomas K Eigentler, Katharina C Kähler, et al.Journal of the National Cancer Institute|September 14, 2014
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaKlaus G Griewank, Rajmohan Murali, Joan Anton Puig-Butille, et al.Blood Neoplasia|April 20, 2026
Targeting the G-protein-coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphomaDeniz Özistanbullu, Karola Bahrami, Monika Doll, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.Nature Genetics|November 24, 2020
Integrated molecular drivers coordinate biological and clinical states in melanomaJake R Conway, Felix Dietlein, Amaro Taylor-Weiner, et al.Oncotarget|September 2, 2015
Analysis of SDHD promoter mutations in various types of melanomaSimone L Scholz, Susanne Horn, Rajmohan Murali, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Genetic evolution of T-cell resistance in the course of melanoma progressionAntje Sucker, Fang Zhao, Birgit Real, et al.The British Journal of Dermatology|July 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trialJürgen C Becker, Anja H Gesierich, Ulrike Leiter, et al.Pageof 17